Advice
Following an abbreviated submission.
Somatropin (Norditropin SimpleXx®) injection is accepted for restricted use within NHS Scotland for the treatment of growth disturbance (current height standard deviation score (SDS) <-2.5 and parental adjusted height SDS <-1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviations, who failed to show catch-up growth (height velocity SDS < 0 during the last year) by 4 years of age or later.
Treatment should be initiated and monitored by a paediatrician with expertise in managing childhood growth disorders and growth hormone therapy.
Download detailed advice34KB (PDF)
Medicine details
- Medicine name:
- Somatropin (Norditropin SimpleXx)
- SMC ID:
- 260/06
- Indication:
- Growth disturbance in short children born small for gestational age
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 12 June 2006